FAGR Fagron SA

Disclosure of notification received from AOC Pharma S.à r.l.

Disclosure of notification received from AOC Pharma S.à r.l.

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET

Disclosure of notification received from AOC Pharma S.à r.l.

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from AOC Pharma S.à r.l.

Notification by AOC Pharma S.à r.l.

  • On 3 October 2024, Fagron received a notification that changes took place in the chain of controlled undertakings through which the shares in Fagron NV are effectively held, be it that no notification threshold has been crossed (downwards nor upwards), and that the total number of shares held by AOC Pharma S.à r.l. has not changed.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 19 December 2023, AOC Pharma S.à r.l. held a total of 8,102,492 voting rights.
  • Based on the denominator of 73,228,904 (total number of voting rights), AOC Pharma S.à r.l. held 11.06% of the total number of voting rights on 19 December 2023.
  • The chain of controlled undertakings is as follows:
    • AOC Pharma S.à r.l. is controlled by Active Ownership Fund SICAV-FIS SCS.
    • Active Ownership Capital S.à r.l. is the general partner of Active Ownership Fund SICAV-FIS SCS.
    • On 1 October 2019, an agreement was concluded by Active Ownership Fund SICAV-FIS SCS regarding the appointment of Active Ownership Corporation S.à r.l. as AIFM (alternative investment fund manager) for Active Ownership Fund SICAV-FIS SCS. Pursuant to this agreement and appointment Active Ownership Corporation S.à r.l will exercise the voting rights with respect to shares held by Active Ownership Fund SICAV-FIS SCS.
    • Active Ownership Corporation S.à r.l. and Active Ownership Capital S.à r.l. are both controlled by Active Ownership Group Ltd. (Cyprus).
    • Active Ownership Group Ltd. (Cyprus) is jointly controlled by two shareholders, Active Ownership Advisors GmbH and Active Ownership Investments Ltd. (Cyprus).
    • Active Ownership Advisors GmbH is controlled by Florian Schuhbauer.
    • Active Ownership Investments Ltd. is controlled by Active Ownership LP (Cyprus), which is controlled by Active Ownership Management Ltd. (Cyprus), which is controlled by Klaus Röhrig.
  • On the date of the notification, 3 October 2024, AOC Pharma S.à r.l. directly holds 11.06% of the voting rights in Fagron NV.
  • The notification of Active Ownership Corporation S.à r.l. can be viewed via this .

Further information

Karin de Jong

Chief Financial Officer

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
08/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Thomas Vranken
  • Thomas Vranken

Fagron FIRST LOOK: Deep-dive into Fagron's warning letter

Following a conference call with management and a readthrough of the warning letter regarding Fagron's Wichita site, our assessment confirms that the issues highlighted in the letter refer mainly to observations that were already known to and being addressed by Fagron since last summer. While the language used by the FDA in the letter is strong, we interpret this in a broader context of the regulator raising the bar on quality standards in the pharmaceutical compounding industry. Three topics we...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Fagron: FDA warning letter received for Wichita

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Thomas Vranken
  • Wim Lewi
 PRESS RELEASE

Fagron updates on FDA communication regarding the June 2024 inspection...

Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future manufacturing ca...

 PRESS RELEASE

Fagron verschaft een update over de FDA-communicatie met betrekking to...

Fagron verschaft een update over de FDA-communicatie met betrekking tot de inspectie in Wichita in juni 2024   Gereglementeerde informatie – voorwetenschap Nazareth (België)/Rotterdam (Nederland), 23 december 2024 – 7:00 CET Fagron verschaft een update over de FDA-communicatie met betrekking tot de inspectie in Wichita in juni 2024 Na de routine-inspectie van de FDA van de vestiging in Wichita in juni 2024, ontving de Vennootschap op 19 december 2024 een waarschuwingsbrief van de FDA (Warning Letter). De waarschuwingsbrief verplicht Fagron om de processen voor het onderzoeken van afwi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch